Innate Pharma (IPHA) Total Debt (2017 - 2025)

Innate Pharma has reported Total Debt for 9 years, with the latest figure at $26.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt fell 20.67% year-over-year to $26.3 million; the trailing twelve-month figure through Dec 2025 stood at $26.3 million (down 20.67% YoY), and the FY2025 full-year result was $26.3 million, down 20.67% from the prior year.
• Total Debt for Q4 2025 stood at $26.3 million, down from $30.6 million in the prior quarter.
• The five-year high for Total Debt was $50.6 million in Q4 2021, with the low at $19.9 million in Q2 2021.
• Historically, Total Debt has averaged $37.5 million across 5 years, with a median of $40.6 million in 2023.
• Annual changes were most pronounced in 2021 — Total Debt sank 99.89% — and 2022, when it jumped 132.89%.
• Innate Pharma's Total Debt stood at $50.6 million in 2021, then dropped by 14.85% to $43.1 million in 2022, then fell by 0.43% to $42.9 million in 2023, then fell by 22.84% to $33.1 million in 2024, then fell by 20.67% to $26.3 million in 2025.
• The last three Total Debt figures came in at $26.3 million (Q4 2025), $30.6 million (Q2 2025), and $33.1 million (Q4 2024), per Business Quant data.